Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban

Stroke

Volumn 44, Issue 3, 2013, Pages 771-778

  Zhou, Wei ^a   Zorn, Markus ^a   Nawroth, Peter ^a   Bütehorn, Ulf ^b   Perzborn, Elisabeth ^b   Heitmeier, Stefan ^b   Veltkamp, Roland ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Anticoagulation; Factor VIIa; Fresh frozen plasma; Prothrombin complex concentrate; Stroke

Indexed keywords

BLOOD CLOTTING FACTOR; COLLAGENASE; FRESH FROZEN PLASMA; HEMOGLOBIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BRAIN HEMORRHAGE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEEDING; HEMATOMA; HEMOSTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME; SPECTROPHOTOMETRY;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; CEREBRAL HEMORRHAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR VIIA; HEMATOMA; HEMOSTATIC TECHNIQUES; MALE; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; MORPHOLINES; PLASMA; THIOPHENES; TREATMENT OUTCOME;

EID: 84876288671     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.675231     Document Type: Article

References (37)

1. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet. 2009;373:155-166.
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867.
3. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
4. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
6. Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007;120:700-705.
7. Flaherty ML, Haverbusch M, Sekar P, Kissela BM, Kleindorfer D, Moomaw CJ, et al. Location and outcome of anticoagulant-associated intracerebral hemorrhage. Neurocrit Care. 2006;5:197-201.
8. Flaherty ML, Tao H, Haverbusch M, Sekar P, Kleindorfer D, Kissela B, et al. Warfarin use leads to larger intracerebral hematomas. Neurology. 2008;71:1084-1089.
9. Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63:1059-1064.
10. Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, et al.; British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin -fourth edition. Br J Haematol. 2011;154:311-324.
11. Eikelboom JW, Weitz JI. New anticoagulants. Circulation. 2010;121:1523-1532.
12. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood. 2010;115:15-20.
13. Foerch C, Arai K, Jin G, Park KP, Pallast S, van Leyen K, et al. Experimental model of warfarin-associated intracerebral hemorrhage. Stroke. 2008;39:3397-3404.
14. Illanes S, Zhou W, Heiland S, Markus Z, Veltkamp R. Kinetics of hematoma expansion in murine warfarin-associated intracerebral hemorrhage. Brain Res. 2010;1320:135-142.
15. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011;42:3594-3599.
16. Illanes S, Zhou W, Schwarting S, Heiland S, Veltkamp R. Comparative effectiveness of hemostatic therapy in experimental warfarin-associated intracerebral hemorrhage. Stroke. 2011;42:191-195.
17. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499-25100
18. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al.; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19.
19. Weinz C, Buetehorn U, Daehler HP, Kohlsdorfer C, Pleiss U, Sandmann S, et al. Pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-in rats and dogs. Xenobiotica. 2005;35:891-910.
20. Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2010;70:703-712.
21. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78:412-421.
22. Hua Y, Schallert T, Keep RF, Wu J, Hoff JT, Xi G. Behavioral tests after intracerebral hemorrhage in the rat. Stroke. 2002;33:2478-2484.
23. Goodnough LT, Shander A. How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. Blood. 2011;117:6091-6099.
24. Rosenberg GA, Mun-Bryce S, Wesley M, Kornfeld M. Collagenaseinduced intracerebral hemorrhage in rats. Stroke. 1990;21:801-807.
25. Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA, et al.; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66:1175-1181.
26. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78:412-421.
27. Lauer A, Cianchetti FA, Van Cott EM, Schlunk F, Schulz E, Pfeilschifter W, et al. Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage. Circulation. 2011;124:1654-1662.
28. Chitlur M. Challenges in the laboratory analyses of bleeding disorders. Thromb Res. 2012;130:1-6.
29. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-1579.
30. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost. 2010;103:815-825.
31. Perzborn E, Tinel H. Feiba reverses the effects of a high dose of rivaroxaban in rats (abstract). Pathophysiol Haemost Thromb. 2008;36:A40 Abstract P0611
32. Gruber A, Marzec UM, Buetehorn U, Hanson SR, Perzborn E. Potential of activated prothrombin complex concentrate and activated factor vii to reverse the anticoagulant effects of rivaroxaban in primates (abstract). Blood. 2008;112:Abstract 38255
33. Marlu R, Hodaj E, Pernod G. Letter by Marlu et al regarding article, "reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects". Circulation. 2012;125:e615; author reply e616.
34. Perzborn E, Trabandt A, Selbach K, Tinel H. Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats (abstract). J Thromb Haemost. 2009;7(suppl 2):379 Abstract PP-MO-1833
35. Harenberg J, Erdle S, Marx S, Krämer R. Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost. 2012;38:178-184.
36. Belayev L, Saul I, Curbelo K, Busto R, Belayev A, Zhang Y, et al. Experimental intracerebral hemorrhage in the mouse: histological, behavioral, and hemodynamic characterization of a double-injection model. Stroke. 2003;34:2221-2227.
37. Kawai N, Nakamura T, Nagao S. Early hemostatic therapy using recombinant factor VIIa in a collagenase-induced intracerebral hemorrhage model in rats. Acta Neurochir Suppl. 2006;96:212-217.